Physician profile
James Fields
NPI 1851904833
$3,264.25
in general payments reported to CMS, 2019-2025
25 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $462 · 2023: $796 · 2024: $112 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.70 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $568.68 | 2021-2023 | Xifaxan |
| Novo Nordisk INC | $269.12 | 2022-2025 | Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $235.40 | 2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $168.84 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.43 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $155.70 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $142.09 | 2023 | Nucala |
| Neurocrine Biosciences, INC. | $118.74 | 2025 | |
| Idorsia Pharmaceuticals US INC | $108.57 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $105.47 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $71.06 | 2021-2023 | Gardasil 9 |
| Janssen Pharmaceuticals, INC | $66.78 | 2025 | Invega Sustenna |
| Astrazeneca Pharmaceuticals Lp | $60.34 | 2021-2023 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $46.35 | 2025 | Aristada, Lybalvi |
| Mylan Specialty L.P. | $45.63 | 2023 | Yupelri |
| Exact Sciences Corporation | $39.57 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $37.85 | 2023 | Freestyle Libre 2 |
| Pfizer INC. | $31.67 | 2023 | |
| Covis Pharma Gmbh | $24.83 | 2022 | |
| Gilead Sciences, INC. | $20.22 | 2023 | |
| Scilex Pharmaceuticals INC. | $20.09 | 2023 | Ztlido |
| Daiichi Sankyo INC. | $17.41 | 2021 | |
| Organon LLC | $16.72 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.